171
Participants
Start Date
September 10, 2019
Primary Completion Date
October 12, 2023
Study Completion Date
February 22, 2024
golidocitinib
golidocitinib will be administered orally as capsules. golidocitinib treatment will be continued until disease progression or intolerant adverse reactions
Winship Cancer Institute, Atlanta
Washington University School of Medicine, St Louis
The University of Texas MD Anderson Cancer Center, Houston
Yale Cancer Center, New Haven
Epworth Hospital, East Melbourne
St Vincent's Hospital Melbourne, Fitzroy
Royal Hobart Hospital, Hobart
St George Hospital, Kogarah
Royal Perth Hospital, Perth
Westmead Hospital, Westmead
Beijing Cancer Hospital, Beijing
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing Hospital, Beijing
Peking University Third Hospital, Beijing
The First Hospital of Jilin University, Changchun
Hunan Cancer Hospital, Changsha
Xiangya Hospital Central South University, Changsha
Sichuan University - West China Hospital, Chengdu
Chongqing University Cancer Hospital, Chongqing
The Second Hospital of Dalian Medical University, Dalian
Guangdong Provincial People's Hospital, Guangzhou
NanFang Hospital of Southern Medical University, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
Hainan General Hospital, Haikou
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Anhui Provincial Cancer Hospital, Hefei
The Second Hospital of Anhui Medical University, Hefei
Shandong Cancer Hospital, Jinan
The First Hospital of Lanzhou University, Lanzhou
Linyi Cancer Hospital, Linyi
Jiangxi Province Cancer Hospital, Nanchang
The First Affiliated Hospital of Nanchang University, Nanchang
Jiangsu Cancer Hospital, Nanjing
Fudan University Shanghai Cancer Center, Shanghai
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai
The First Affiliated Hospital of Soochow University, Suzhou
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Xiamen University, Xiamen
Henan Cancer Hospital, Zhengzhou
Inje University Busan Paik Hospital, Busan
Pusan National University Hospital, Busan
Keimyung University Dongsan Hospital, Daegu
National Cancer Center, Goyang
Chonbuk National University Hospital, Jeonju
Seoul National University Bundang Hospital, Seongnam
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Samsung Medical Center, Seoul
Lead Sponsor
Dizal Pharmaceuticals
INDUSTRY